Jordan Sheldon, Zielinski Margaret, Kortylewski Marcin, Kuhn Taylor, Bystritsky Alexander
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
Focus (Am Psychiatr Publ). 2022 Jan;20(1):64-70. doi: 10.1176/appi.focus.20210028. Epub 2022 Jan 25.
In the past, psychotherapy and neuropharmacological approaches have been the most common treatments for disordered thoughts, moods, and behaviors. One new path of brain therapeutics is in the deployment of noninvasive approaches designed to reprogram brain function at the cellular level. Treatment at the cellular level may be considered for a wide array of disorders, ranging from mood disorders to neurodegenerative disorders. Brain-targeted biological therapy may provide minimally invasive and accurate delivery of treatment. The present article discusses the hurdles and advances that characterize the pathway to this goal.
过去，心理治疗和神经药理学方法一直是治疗紊乱的思维、情绪和行为最常用的方法。脑治疗学的一条新途径是采用旨在在细胞水平上重新编程脑功能的非侵入性方法。从情绪障碍到神经退行性疾病等各种各样的疾病都可以考虑进行细胞水平的治疗。脑靶向生物疗法可以提供微创且精确的治疗。本文讨论了实现这一目标的途径所具有的障碍和进展。
